Difference between revisions of "Cyclophosphamide (Cytoxan)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Chronic lymphocytic leukemia (CLL/SLL)" to "[[Chronic lymphocytic leukemia") |
m |
||
| Line 42: | Line 42: | ||
*[[Primary mediastinal B-cell lymphoma]] | *[[Primary mediastinal B-cell lymphoma]] | ||
*[[Prostate cancer]] | *[[Prostate cancer]] | ||
| + | *[[Rhabdomyosarcoma]] | ||
*[[Small cell lung cancer]] | *[[Small cell lung cancer]] | ||
*[[T-cell acute lymphoblastic leukemia]] | *[[T-cell acute lymphoblastic leukemia]] | ||
| Line 56: | Line 57: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*11/16/1959: initial FDA approval | *11/16/1959: initial FDA approval | ||
| + | *Unclear date: Approved for malignant lymphomas: [[Hodgkin lymphoma|Hodgkin’s disease]], [[Chronic lymphocytic leukemia|lymphocytic lymphoma]], mixed-cell type lymphoma, [[Diffuse large B-cell lymphoma|histiocytic lymphoma]], [[Burkitt lymphoma]]; [[multiple myeloma]], leukemias, [[Cutaneous T-cell lymphoma|mycosis fungoides]], [[neuroblastoma]], [[Ovarian cancer|adenocarcinoma of ovary]], [[retinoblastoma]], [[Breast cancer|breast carcinoma]] | ||
==Also known as== | ==Also known as== | ||
| Line 172: | Line 174: | ||
[[Category:Primary mediastinal B-cell lymphoma medications]] | [[Category:Primary mediastinal B-cell lymphoma medications]] | ||
[[Category:Prostate cancer medications]] | [[Category:Prostate cancer medications]] | ||
| + | [[Category:Rhabdomyosarcoma medications]] | ||
[[Category:Small cell lung cancer medications]] | [[Category:Small cell lung cancer medications]] | ||
[[Category:T-cell acute lymphoblastic leukemia medications]] | [[Category:T-cell acute lymphoblastic leukemia medications]] | ||
Revision as of 02:17, 5 August 2019
General information
Class/mechanism: Alkylating agent; transformed primarily in the liver to active metabolites which alkylate and crosslink DNA.[1][2]
Route: IV, PO
Extravasation: irritant or neutral, depending on reference; n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acquired coagulopathy
- Acute myeloid leukemia
- Adult T-cell leukemia/lymphoma
- Anaplastic glioma
- Anaplastic large cell lymphoma
- B-cell acute lymphoblastic leukemia
- Bladder cancer
- Breast cancer
- Burkitt lymphoma
- Central nervous system (CNS) cancer
- Chronic lymphocytic leukemia
- Chronic myelogenous leukemia
- CNS lymphoma
- Diffuse large B-cell lymphoma
- Ewing sarcoma
- Follicular lymphoma
- Glioblastoma
- HIV-associated lymphoma
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Large granular lymphocytic leukemia
- Light-chain (AL) amyloidosis
- Mantle cell lymphoma
- Marginal zone lymphoma
- Mediastinal gray-zone lymphoma
- Medulloblastoma
- Multiple myeloma
- Osteosarcoma
- Peripheral T-cell lymphoma
- Pheochromocytoma
- Plasma cell leukemia
- Post-transplant lymphoproliferative disorder
- Primary mediastinal B-cell lymphoma
- Prostate cancer
- Rhabdomyosarcoma
- Small cell lung cancer
- T-cell acute lymphoblastic leukemia
- Thymoma
- Transformed lymphoma
- Waldenström macroglobulinemia
Patient drug information
- Cyclophosphamide (Cytoxan) package insert[1]
- Cyclophosphamide (Cytoxan) patient drug information (Chemocare)[3]
- Cyclophosphamide (Cytoxan) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 11/16/1959: initial FDA approval
- Unclear date: Approved for malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma
Also known as
- Code names: Asta B 518, B-518, WR-138719
- Generic names: CP monohydrate, CPM, cyclophosphamid monohydrate, cyclophosphamide monohydrate
- Brand names:
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Alkyloxan | Biodoxan | Carloxan | Ciclofosfamida | Ciclokebir | Cicloxal | Clafen | Claphene |
| Cyclam | Cycloblastin | Cycloblastine | CYCLO-cell | Cycloferon | Cyclomide | Cyclophar | Cyclophospham |
| Cyclophosphamid | Cyclophosphane | Cyclostin | Cyclostine | Cyclotox | Cycloxan | Cycram | Cydoxan |
| Cyklofosfamid | Cyphos | Cytophosphan | Cytoxan | Cytoxan Lyophilized | Endoxan | Endoxan-N | Endoxana |
| Enduxan | Formitex | Fosfaseron | Genoxal | Genuxal | Hidrofosmin | Ledoxan | Ledoxina |
| Mitoxan | Neophos | Neosar | Oncomide | Oncophos | Procytox | Revimmune | Sendoxan |
| Siklofos | Syklofosfamid | Tymtran | Zuviphos | Zycram | Zytoxan | ||
References
Categories:
- Drugs
- Intravenous medications
- Oral medications
- Irritant chemotherapy
- Neutral chemotherapy
- Alkylating agents
- Nitrogen mustards
- Immunosuppressants
- Acquired coagulopathy medications
- Acute myeloid leukemia medications
- Adult T-cell leukemia/lymphoma medications
- Anaplastic glioma medications
- Anaplastic large cell lymphoma medications
- B-cell acute lymphoblastic leukemia medications
- Bladder cancer medications
- Breast cancer medications
- Burkitt lymphoma medications
- CNS lymphoma medications
- Chronic lymphocytic leukemia medications
- Chronic myelogenous leukemia medications
- Diffuse large B-cell lymphoma medications
- Ewing sarcoma medications
- Follicular lymphoma medications
- Glioblastoma medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Large granular lymphocytic leukemia medications
- Light-chain (AL) amyloidosis medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Mediastinal gray-zone lymphoma medications
- Medulloblastoma medications
- Multiple myeloma medications
- Osteosarcoma medications
- Peripheral T-cell lymphoma medications
- Pheochromocytoma medications
- Plasma cell leukemia medications
- Post-transplant lymphoproliferative disorder medications
- Primary mediastinal B-cell lymphoma medications
- Prostate cancer medications
- Rhabdomyosarcoma medications
- Small cell lung cancer medications
- T-cell acute lymphoblastic leukemia medications
- Thymoma medications
- Transformed lymphoma medications
- Waldenström macroglobulinemia medications
- FDA approved in 1959
- PMDA approved drugs
- WHO Essential Cancer Medicine